Used in the treatment of hormone-dependent cancers such as breast and prostate cancer. Acts as a dual inhibitor of steroid sulfatase and 17α-hydroxylase/17,20-lyase (CYP17), reducing the production of active estrogens and androgens. This helps suppress tumor growth that depends on these hormones. Investigated in clinical trials for postmenopausal women with advanced breast cancer and in men with castration-resistant prostate cancer. Shows potential in overcoming resistance to conventional hormone therapies by targeting multiple pathways in steroid synthesis.